Revelation Biosciences Inc. reported a net loss of $1.9 million, or $(1.77) per share, for the three months ended September 30, 2025, compared to a net loss of $2.2 million, or $(40.2) per share, for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $6.4 million, or $(9.8) per share, down from a net loss of $13.3 million, or $(354.1) per share, for the same period in 2024. Net cash used for operating activities for the nine-month period was $6.3 million, compared to $14.6 million in the prior year. As of September 30, 2025, cash and cash equivalents totaled $12.7 million, up from $6.5 million at December 31, 2024, primarily due to proceeds from a May 2025 public offering and a September 2025 warrant inducement, which brought in $9.6 million. During the period, the company announced top-line results from its PRIME clinical study and plans to meet with the FDA regarding the clinical development path for its Gemini program.